Bioventix (GB:BVXP) has released an update.
Bioventix PLC reported a 6% increase in revenue to £13.6 million and a 5% rise in profit before tax to £10.6 million for the fiscal year ending June 2024. The company’s significant revenue is derived from their high-affinity monoclonal antibodies used in clinical diagnostics, seeing particular growth in the vitamin D and thyroid function sectors. While facing challenges in troponin royalties, Bioventix is optimistic about new applications in cardiac risk assessment and continued growth in the Chinese market.
For further insights into GB:BVXP stock, check out TipRanks’ Stock Analysis page.
